Stock Financial Ratios

ASX:RMD / RESMED INC financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.00
Volume0.00
Market Cap ($M)0.00
Enterprise Value ($M)-858.90
Book Value ($M)1,960.27
Book Value / Share13.76
Price / Book0.00
NCAV ($M)135.78
NCAV / Share0.95
Price / NCAV0.00
Income Statement (mra) ($M)
Revenue2,066.74
EBITDA425.80
Net Income342.28
Balance Sheet (mrq) ($M)
Cash & Equivalents858.90
Cash / Share0.00
Assets0.00
Liabilities0.00
Quick Ratio3.82
Current Ratio4.57
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.11
Return on Assets (ROA)0.11
Return on Equity (ROE)0.20
Identifiers and Descriptors
Central Index Key (CIK)943819
Industry Groups
SIC 3841 - Surgical and Medical Instruments and Apparatus
Share Statistics
Common Shares Outstanding142,209,115
Weighted Average Number Of Diluted Shares Outstanding142,453,000
Common Stock Shares Outstanding142,174,724
Weighted Average Number Of Shares Outstanding Basic141,360,000
Weighted Average Number Diluted Shares Outstanding Adjustment1,093,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00
Assets Current Per Share0.00
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Liabilities Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Other Current Per Share0.00
Cash Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Liabilities Current Per Share0.00
Debt Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Cash And Equivalents Per Share6.03

Related News Stories

Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up

2018-02-07 zacks
Haemonetics Corporation (HAE - Free Report) reported adjusted earnings per share (EPS) of 62 cents in the third quarter of fiscal 2018, a 44% surge year over year. The bottom line also beat the Zacks Consensus Estimate of 41 cents. The metric was favourably attributed by 10 cents of lower tax rate and 4 cents of currency translation, partly offset by a couple of cents’ dilution on increased share count. (16-0)

LabCorp (LH) Q4 Earnings Beat Estimates, '18 View Promising

2018-02-06 zacks
Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp reported fourth-quarter 2017 adjusted earnings per share (EPS) of $2.45, up 13.9% from the year-ago quarter. The bottom line also exceeded the Zacks Consensus Estimate by 3.4%. One-time benefit related to the Tax Cuts and Jobs Act in the reported quarter, affected adjusted EPS by 5 cents, approximately. (3-0)

Align Technology Banks on Global Growth, Competition Rife

2018-02-06 zacks
On Feb 1, we issued an updated research report on Align Technology, Inc. (ALGN - Free Report) . The stock carries a Zacks Rank #3 (Hold). (42-0)

Phibro Animal (PAHC) Beats on Q2 Earnings, Raises Guidance

2018-02-06 zacks
Phibro Animal Health Corporation (PAHC - Free Report) reported adjusted earnings per share (EPS) of 44 cents in the second quarter of fiscal 2018, up 12.8% year over year. Adjusted EPS surpassed the Zacks Consensus Estimate of 39 cents. According to the company, the year-over-year improvement was primarily driven by a higher gross profit ratio, reduced interest expenses and a lower effective income tax rate. (9-0)

Genomic Health (GHDX) Oncotype DX GPS Test Results Positive

2018-02-06 zacks
Genomic Health, Inc. (GHDX - Free Report) announced that use of the Oncotype DXGenomic Prostate Score (GPS) test leads to considerably higher use of active surveillance at six and 12 months compared to no testing within the same time period. (15-0)